Table 1.
The characteristics of RTRs undergoing RRP or RPP compared to a contemporary series of non-RTRs with clinically localised prostate cancer treated with RRP or RPP by the same surgeon. There were no significant differences between the groups.
| Variable | RTRs |
Controls |
||
|---|---|---|---|---|
| RRP | RPP | RRP | RPP | |
| Number of patients | 16 | 7 | 100 | 100 |
| Mean (range): | ||||
| Age (years) | 64 (59–67) | 64 (52–69) | 62.6 (49–72) | 63.8 (42–74) |
| Preop. PSA level (ng/mL) | 4.5 (3.0–17.5) | 4.3 (3.6–10.5) | 13.4 (1.6–39) | 9.5 (2.5–15.6) |
| Biopsy Gleason score | 6.4 (6–8) | 6.3 (4–8) | 6.2 (4–8) | 6.1 (4–8) |
| Operative duration (min) | 125 (105–215) | 154 (132–215) | 112 (85–150) | 165 (124–256) |
| Blood loss (mL) | 390 (100–1500) | 520 (250–1500) | 320 (150–1800) | 650 (450–1500) |
| Hospital stay (days) | 7.9 (5–13) | 9.0 (5–14) | 6.5 (3–14) | 9.0 (8–17) |
| Duration of transurethral | ||||
| Catheterisation (days) | 5.9 (5–12) | 8.5 (7–13) | 5.6 (4–19) | 8.0 (7–12) |